Chelsea Therapeutics - Best Pharma Stocks of 2007

Company: Chelsea Therapeutics
Starting stock price: $3.82
Ending stock price: $7.85
Percent Change: 92.41%

Details: Chelsea Therapeutics is developing therapies for a number of inflammatory conditions. In 2007 the company won orphan status for Droxidopa, which treats low blood pressure stemming from Parkinson's or from multiple-system atrophy. The drug already has orphan status in the U.S. and is in Phase III trials. Chelsea also has the drug candidate CH-1504 in Phase II trials for rheumatoid arthritis, psoriasis and inflammatory bowel disease.

More News:
Chelsea wins European orphan status. Report
FDA grants Droxidopa orphan drug status. Report

Chelsea Therapeutics - Best Pharma Stocks of 2007
Read more on

Suggested Articles

Bluebird Bio has overcome a manufacturing hiccup that looked like it would delay its gene therapy launch in Europe until next year.

Lilly's top U.S. executive is on his way out. Enrique Conterno, who also heads up Lilly's global diabetes business, will step down at year's end.

GlaxoSmithKline, Pfizer, Sanofi and Boehringer Ingelheim are facing lawsuit claims that they failed to test for possible carcinogens in Zantac.